We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ONT Oxford Nanopore Technologies Plc

-3.30 (-2.96%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nanopore Technologies Plc LSE:ONT London Ordinary Share GB00BP6S8Z30 ORD GBP0.0001
  Price Change % Change Share Price Shares Traded Last Trade
  -3.30 -2.96% 108.20 1,085,523 16:35:20
Bid Price Offer Price High Price Low Price Open Price
108.20 108.60 112.80 107.00 112.80
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169.67M -154.51M -0.1798 -6.04 933.42M
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:51 O 5,000 108.20 GBX

Oxford Nanopore Technolo... (ONT) Latest News

Oxford Nanopore Technolo... (ONT) Discussions and Chat

Oxford Nanopore Technolo... Forums and Chat

Date Time Title Posts
18/5/202418:08OXFORD NANOPORE 1,398
10/5/200409:41Ј8m boost for Online Travel473
29/1/200421:48Online Travel - Superb chart and fundamentals3
19/12/200317:11ONT - 4 new contracts worth Ј7million310
15/10/200303:30Online Travel Corporation962

Add a New Thread

Oxford Nanopore Technolo... (ONT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Oxford Nanopore Technolo... (ONT) Top Chat Posts

Top Posts
Posted at 18/5/2024 09:20 by Oxford Nanopore Technolo... Daily Update
Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 111.50p.
Oxford Nanopore Technolo... currently has 859,503,324 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £933,420,610.
Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -6.04.
This morning ONT shares opened at 112.80p
Posted at 29/4/2024 21:39 by 32v31today
One take I had from the recent pacb update was how terrible the end market is / has been. I think it hit them more than others. LSTools seem to have reported a better than expected tough period and looking at things picking up further in H2. This isn't based on a particularly deep dive, but nervousness from pacb will hit ONT. Bottom line for me, hopefully end market is picking up from here. I think Bruce nailed calling these prices a while back. My take is that, long term, this is massively mispriced by the market, and so an opportunity (unless you're dipping in and out every 5 minutes, in which case, who knows) . I'd expect to see the price improve very materially during 2024 (so expect it to go down ;) )My view on current price decline is potentially influenced big holders selling down and end market has been really difficult recently. Both of which have hopefully turned/ turning, both of which are hopefully good for share price. That said I've not done any sums on that.Reasons to buy not sell in my book.
Posted at 22/4/2024 11:58 by brucie5
"Non pasaran!"
Well maybe. Small buys look like being soaked up.
Anyone with level 2 access care to share what they see this morning?
My conjecture continues to be that this is capitulation. I'm surprised that anyone left in would be still trying to sell.
As yet nothing to send the share the other way, except some correction of the oversold situation on the chart. The 50sma, with which the share price not infrequently makes contact on the way down is at 1.30p. So best guess is that we could see a 25% correction the other way without even touching the current trend.
In the medium term I continue to look for the recapturing of the £1 level before we see a credible base begin to build.
All on the tea leaves, obviously, so NAI.
Posted at 13/4/2024 12:27 by 74tom
Last few thoughts from me for now;

1. The decline has been driven by low volume, with the average daily value of shares traded in 2024 sitting at £2m (2021 was £12.7m, 2022 was £5.4m and 2023 was £3m). A bottom normally forms when volume is high, so there is no capitulation from large shareholders, it's just a sustained downward pressure.

2. The heavy shorting of US listed arch rival Pacbio is undoubtedly influencing ONT's share price. From my research there appears to be a significant chance of them becoming insolvent, with their market cap of $844m exceeded by $892m of Convertible note debt, and cash of $631m declining by ~$80m per quarter. Cumulative shares held short were 49m at 28th March, which is ~18% of it's float, up from 10% this time last year. Conversely to ONT, PACB has sold off on significantly higher than average volume, as you can see from @Bamboo2,s chart above.

It will be very interesting to see how things play out this year, if PACB are commercially impaired then it can only be a good thing for ONT in my opinion.
Posted at 23/3/2024 12:01 by bamboo2
Price action is far from ideal.

This is a weak sector at present. Hopefully it should change at some point, as massive expansion of sequencing around the world is forecast. The UK market is discounting many growth and tech stocks, and analysts have taken against ONT management and their attempts to be realistic in the face of unexpected problems, such as the ban on export of devices containing NVDA chips to China.

On the positive side, ONT has almost completed the planned increases of staff in technical, manufacturing and sales functions. Naturally, this should increase turnover. Accuracy continues to improve and customer sentiment is at all time highs. The new ASIC should get an airing in May 2024.

Management have so far made no attempt to extend the life of LAT shares that expire in June 2024, which means takeover potential could lift the valuation. There are a large number of organisations around the world that could currently buy the whole company for pocket money.

I find ONT one of the most exciting companies in the UK, and despite a losing position at present will continue to hold for the long term.
Posted at 22/3/2024 16:53 by minsky
x = ONT share price;
while x > 0 {
bamboo2 posts article about ONT success;
x = x-2;
Posted at 04/3/2024 16:20 by 74tom
Quite extraordinary to think that the EV here is now ~£600m

I do think the recent accelerated decline is mainly due to PACB's share price performance.

Today, at fresh 1 year lows, they have a market cap of $1.29b.

At 31/12 they had $631.4m of cash & $891m of CLN debt, so their EV was $1.549b, which is around double that of ONT.

If you compare the financial performance of each company, ONT is far superior.

PACB grew top line product revenue by 69% YoY, however this translated to a pathetic 8% improvement in gross profit from $49m to $52m. Operating losses were $334m on gross margins of 26%...

ONT's gross margins are more than double at 57%, and their H123 gross profit was greater than PACB's entire FY23 number.

Hard to fathom how ONT can remain on LSE much longer.
Posted at 04/12/2023 19:47 by bamboo2
Some detective work on the remainder of the Woodford holding [formerly the Woodford Patient Capital Trust holding] which is now managed by Schroders under the ticker INOV.

Nortrust Nominees Limited A/C WIZ02(7) Prior to admission 25,927,100 3.65%
Post admission 23,334,390 2.94%

Beneficial interest in these Ordinary Shares was held by Schroder UK Public Private Trust plc under the ticker SUPP, now known as INOV.

Day/mth/yr Holding value ONT share price quantity held

31/12/2022 £56,529,000 2.466 = 22,923,357
30/06/2023 £44,000,000 2.132 = 20,599,250
30/09/2023 £42,100,000 2.056 = 19,990,272

Therefore, at eod on 30/9/2023 INOV held 2.33%

They are committed to 'rebalancing' their portfolio, so I expect the selling to continue.
Posted at 10/11/2023 08:56 by bamboo2
This paper goes a long way to explaining why the ongoing UK clinical trial of Illuminas GRAIL should be shown the door, because it is ineffective, slow, expensive and outdated compared with ONT's long read capability.


Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.

The paper explained


Current sequencing methods based on short-read technologies to analyze cell-free DNA (cfDNA) as a liquid biopsy in cancer patients have limitations. These include a bias toward shorter cfDNA populations and long waiting times for data. The Oxford Nanopore Technologies (ONT) platform offers a portable and fast alternative, capable of sequencing any length of cfDNA fragment. However, its potential for analyzing cfDNA from cancer patients remains underexplored.


Plasma and urine samples from lung and bladder cancer patients, as well as healthy controls, were sequenced with a MinION ONT and compared to a short-read sequencer. The ONT platform successfully retrieved cfDNA somatic copy number aberrations within 24 h of sampling, and with comparable sensitivity to short-read technologies.

The study also demonstrated that ONT sequencing could recover long cfDNA fragments in both plasma and urine samples, contrary to the canonical belief that cfDNA is predominantly short and fragmented. The presence of tumor-derived signal in these long fragments is confirmed in not only humans but also using a xenograft model. In addition to the size profile, other fragmentomic features could be retrieved from the cfDNA data.


In conclusion, the ONT sequencing provided a fast and accurate analysis of cfDNA from liquid biopsy samples. It allowed the detection of copy number aberrations, estimation of tumor fraction, and recovery of long cfDNA fragments. The ONT platform's deployability and short turnaround time make it a promising tool for liquid biopsy analysis.
Posted at 19/10/2023 07:56 by bamboo2
BioMérieux makes strategic investment in Oxford Nanopore

19 October 2023


Oxford, UK and Marcy-l'Étoile, France, 19 October 2023. Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics ("IVD") today announce that bioMérieux is making an immediate GBP70M investment in Oxford Nanopore.

In addition, bioMérieux expects to make further market purchases of Oxford Nanopore's shares from time to time, up to a further 3.5% of Oxford Nanopore's shares, subject to availability and price.

The investment strengthens the relationship between the two companies, further aligning with Oxford Nanopore's increasing focus on clinical markets through a partnership announced in April this year. This investment will support development for products in Oxford Nanopore's portfolio to serve IVD markets in conjunction with bioMérieux's commitment to advancing global public health.

Through this partnership and this investment, the two companies intend to leverage Oxford Nanopore's ground-breaking nanopore-based IVD solution and bioMérieux's IVD expertise in R&D, Regulatory, Medical and Market Access. As part of the transaction, the two companies will establish an IVD Advisory Board to advance nanopore technology into routine clinical use.

Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features and advances in single-nucleotide sequencing accuracy of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples.

Together, the companies are driving to meet a significant unmet need in the clinical and diagnostic markets- an opportunity where nanopore sequencing is uniquely suited to deliver impact where information-rich, rapid, accessible, and affordable sequencing are critical.

Oxford Nanopore reconfirms its guidance to be adjusted EBITDA breakeven by the end of 2026.

Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented: "With bioMérieux's strategic investment and our shared commitment to innovation, we are poised to accelerate the development of nanopore-based IVD solutions. This investment will enable us to deliver rapid, accessible, and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide."

Pierre Boulud, bioMérieux CEO, commented: "This investment will reinforce our existing partnership with Oxford Nanopore and provide more resources for the development of innovative IVD solutions. Drawing on our six decades of expertise in the in vitro diagnostic space, we consider that the new generation of sequencing technology developed by Oxford Nanopore holds promise to answer future diagnostic needs and will further improve patient care, in particular against the ever-growing infectious diseases threat."

Transaction structure

-- bioMérieux has agreed to subscribe for 29,025,326 ordinary shares (which equates to 3.5% of Oxford Nanopore's voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the "Subscription"), conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly GBP70 million.

-- Applications will be made to the Financial Conduct Authority and the London Stock Exchange for the shares issued pursuant to the Subscription to be admitted to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange ("Admission").

-- Admission is expected to occur on Monday 23 October 2023.
-- The Subscription price of 238.08p per share is equal to the 6-month volume weighted average price as at 13 October 2023.

As part of the Subscription, subject to certain customary exceptions, bioMérieux undertakes to:

-- For a period of 5 years, not acquire or agree to acquire any interests in Oxford Nanopore's shares which would result in it and its affiliates having an interest exceeding 9.9% of the issued share capital of Oxford Nanopore (provided that this restriction shall be suspended for so long as Oxford Nanopore is in an offer period (included in the Definitions of the City Code on Takeovers and Mergers (the "Code")), and in the case of an offer period which is commenced by an announcement under Rule 2.4 of the Code, for a one month period after the cessation of such offer period);

-- not dispose of any shares in Oxford Nanopore for 12 months, subject to certain limited exceptions; and

-- comply with certain orderly marketing obligations for a period of four years after expiry of the 12-months lock-up period, subject to certain limited exceptions.
Posted at 19/6/2023 11:35 by scrutable
Many lab workers will inevitably resist change from ILL to ONT even where it is an obviously better process. ONT presages loss of work. For some types of short code work it won't matter much and ILL will still have an economic edge. The least busy labs will resist change. That's normal. Forking out for the ONT kit will deter many where the volume of such work is low.

The ILL share price was in continuous fall for 12 months from June 2021 since when the trend channel has only flat lined. .An investment in ONT has, for the last three months, shown escalating advantage over ILL, which can resist this divergence by beginning to pay a dividend - but this would only stave off the inevitable.

ILL will soon be 'yesterday's share unless it exploits the financial power of Wall Street to effect a takeover
of ONT which must already be being considered as a survival strategy.

The UK does not have many global leaders.

Our crown jewels are always underpriced
Oxford Nanopore Technolo... share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock